Beyond weight loss: what SELECT actually established
A foundational reading of a cardiovascular outcomes trial—and the boundaries of its result.
Read the briefing ↗Independent research & industry intelligence
Peptide science.
In perspective.
A free briefing on the studies, trials, regulatory decisions and companies shaping the peptide field. Primary sources, clearly explained.
Explore the journal ↗The weekly briefing01 / PEER-REVIEWED RESEARCH02 / CLINICAL TRIALS03 / REGULATION04 / LISTED COMPANIES
THE FEATURE · RESEARCH CHECKED 30 OCTOBER 2026
Retatrutide.
Beyond the scales.
Could its future extend to the heart, kidneys, liver and brain? Explore the human findings, the ongoing trials and the early animal research—without confusing potential with proof.
CardiovascularAlzheimer’s & cognitionLiver healthKidney healthSleep apnoeaBlood glucose
Cardiovascular outcomes remain under investigation. Brain findings are preclinical; a human Alzheimer’s benefit has not been established. Explore the primary sources ↗
Read the full feature ↗LEGAL & REGULATORY FEATURE · UNITED STATES
Retatrutide.
The classification battle.
Why Lilly is challenging FDA over “drug” versus “biologic”—what the court decided, FDA’s latest response, and why classification is not approval.
Primary court documents · FDA’s 2 October 2026 letter · Separate from lawsuits against sellers
Read the legal feature ↗The opening collection
Read beyond the headline.
Four initial issues · Editorial drafts
Retatrutide: read the phase 3 paper, not just the headline
TRIUMPH-1 adds randomized evidence; the analysis method still matters.
Read the briefing ↗The regulatory boundary around research peptides
US and Australian authorities distinguish scientific interest from lawful therapeutic supply.
Read the briefing ↗Company intelligence: separating a pipeline from a valuation
Zealand Pharma provides a case study in how we will read listed peptide businesses.
Read the briefing ↗Our editorial commitment
Trace every claim.
Follow scientific and financial statements back to the original paper, registry, regulator or company filing.
Name the uncertainty.
Separate demonstrated findings, sponsor statements and editorial interpretation. Keep limitations visible.
Keep the boundary.
No human-use protocols, personalised treatment advice or stock tips.
The weekly briefing
A clearer view.
Once a week.
Research, trials, regulation and industry. Free to read, with no paid tier planned.
Subscribe to Peptide Cheat.
Join the free newsletter for research, trials and industry developments. Confirm your subscription through our email provider.
Subscribe free ↗Initial release. Research profiles marked as incomplete are still being developed. Subscribe through our newsletter provider using the signup link.
WATCH & LISTEN
The conversations worth examining.
Popular video interviews with physicians discussing peptides, weight-loss medicines and the questions behind the headlines.
≈5 million YouTube views
Peptide Expert: What Do Peptides Actually Do?
Dr Alex Tatem
Interviewed by Steven Bartlett
Peptides explained · GLP-1s · Retatrutide
A broad physician interview on peptide interest and metabolic health. Clinical anecdotes and proposed uses require separate evidence checks.
Watch on YouTube ↗≈946,000 YouTube views
Peptides: The Science, Uses & Safety
Dr Abud Bakri
Interviewed by Andrew Huberman
BPC-157 · GLP-1s · Retatrutide · Safety
A physician discussion covering peptide biology, sourcing and the gap between animal and human research.
Watch on YouTube ↗≈669,000 YouTube views
Peptide & Hormone Therapies for Health, Performance & Longevity
Dr Craig Koniver
Interviewed by Andrew Huberman
Peptides · GLP-1s · Hormones
A wide-ranging clinical-practice conversation. Inclusion does not validate treatment claims, sourcing advice or protocols discussed.
Watch on YouTube ↗≈3.7 million YouTube views
The Biology of Slowing & Reversing Aging
David Sinclair, PhD
Genetics researcher · Interviewed by Andrew Huberman
Longevity · Ageing biology · Cellular mechanisms
A broad ageing-research conversation, not a peptide-specific clinical review. The episode title reflects the publisher’s framing; it does not establish that ageing reversal has been demonstrated in humans.
Watch on YouTube ↗Rounded YouTube view counts checked 30 October 2026; counts change over time. Interview selections are drafts pending full-episode editorial review.
Conversation is a starting point, not clinical proof. These are third-party interviews, not peer-reviewed evidence or endorsements of products, suppliers or protocols. Explore our peptide research directory, BPC-157 research library and HRT evidence alongside them.
CONTACT & COLLABORATIONS
Good conversations.
Better understanding.
We welcome thoughtful collaborations with creators, clinicians, researchers and people working across the peptide, wellness and life-sciences industries.
- Creators & influencers: evidence-led interviews, educational content and audience collaborations.
- Clinicians & researchers: expert commentary, study discussions and research explainers.
- Industry participants: trial updates, scientific developments, company disclosures and interview opportunities.
- Media & podcast hosts: editorial conversations, guest contributions and cross-publication projects.
Start a conversation
Tell us who you are, what you have in mind and why it would be useful to our readers. Include your website or channel, relevant research links and any commercial interests.
hello@peptidecheat.comDiscuss a collaboration ↗
Research tips, corrections and general publication enquiries are also welcome. Please do not send personal medical records or requests for individual treatment advice.
Editorial independence: collaboration does not guarantee coverage or endorsement. Contributions are subject to source checks and editorial review. Relevant financial interests and commercial relationships must be disclosed. We do not offer paid favourable coverage, subscriber-list sales or promotions for unapproved peptide products.